• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

英国超声心动图学会经胸超声心动图评估心脏淀粉样变性指南。

British Society of Echocardiography guideline for the transthoracic echocardiographic assessment of cardiac amyloidosis.

作者信息

Moody William E, Turvey-Haigh Lauren, Knight Daniel, Coats Caroline J, Cooper Robert M, Schofield Rebecca, Robinson Shaun, Harkness Allan, Oxborough David L, Gillmore Julian D, Whelan Carol, Augustine Daniel X, Fontana Marianna, Steeds Richard P

机构信息

Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Foundation Trust, Mindelsohn Way, Edgbaston, Birmingham, B15 2TH, UK.

Institute of Cardiovascular Science, College of Medical and Dental Science, University of Birmingham, Birmingham, UK.

出版信息

Echo Res Pract. 2023 Aug 31;10(1):13. doi: 10.1186/s44156-023-00028-7.

DOI:10.1186/s44156-023-00028-7
PMID:37653443
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10468878/
Abstract

These guidelines form an update of the BSE guideline protocol for the assessment of restrictive cardiomyopathy (Knight et al. in Echo Res Prac, 2013). Since the original recommendations were conceived in 2013, there has been an exponential rise in the diagnosis of cardiac amyloidosis fuelled by increased clinician awareness, improvements in cardiovascular imaging as well as the availability of new and effective disease modifying therapies. The initial diagnosis of cardiac amyloidosis can be challenging and is often not clear-cut on the basis of echocardiography, which for most patients presenting with heart failure symptoms remains the first-line imaging test. The role of a specialist echocardiographer will be to raise the suspicion of cardiac amyloidosis when appropriate, but the formal diagnosis of amyloid sub-type invariably requires further downstream testing. This document seeks to provide a focused review of the literature on echocardiography in cardiac amyloidosis highlighting its important role in the diagnosis, prognosis and screening of at risk individuals, before concluding with a suggested minimum data set, for use as an aide memoire when reporting.

摘要

本指南是对评估限制型心肌病的BSE指南协议的更新(Knight等人,《Echo Res Prac》,2013年)。自2013年提出最初建议以来,由于临床医生意识的提高、心血管成像技术的改进以及新型有效疾病修饰疗法的出现,心脏淀粉样变性的诊断呈指数级增长。心脏淀粉样变性的初步诊断可能具有挑战性,基于超声心动图往往并不明确,而对于大多数出现心力衰竭症状的患者,超声心动图仍是一线成像检查。专业超声心动图医生的作用是在适当的时候提高对心脏淀粉样变性的怀疑,但淀粉样蛋白亚型的正式诊断总是需要进一步的下游检测。本文献旨在对心脏淀粉样变性中超声心动图的文献进行重点综述,突出其在诊断、预后及高危个体筛查中的重要作用,最后给出一个建议的最小数据集,用作报告时的辅助记忆。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d432/10468878/a13a15b04022/44156_2023_28_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d432/10468878/e421d5d48394/44156_2023_28_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d432/10468878/c634d8de8370/44156_2023_28_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d432/10468878/a13a15b04022/44156_2023_28_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d432/10468878/e421d5d48394/44156_2023_28_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d432/10468878/c634d8de8370/44156_2023_28_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d432/10468878/a13a15b04022/44156_2023_28_Fig3_HTML.jpg

相似文献

1
British Society of Echocardiography guideline for the transthoracic echocardiographic assessment of cardiac amyloidosis.英国超声心动图学会经胸超声心动图评估心脏淀粉样变性指南。
Echo Res Pract. 2023 Aug 31;10(1):13. doi: 10.1186/s44156-023-00028-7.
2
Echocardiographic assessment of cardiac amyloidosis.超声心动图评估心脏淀粉样变性。
Heart Fail Rev. 2022 Sep;27(5):1505-1513. doi: 10.1007/s10741-021-10165-y. Epub 2021 Aug 30.
3
Diagnostic imaging of cardiac amyloidosis.心脏淀粉样变性的诊断影像学。
Nat Rev Cardiol. 2020 Jul;17(7):413-426. doi: 10.1038/s41569-020-0334-7. Epub 2020 Feb 10.
4
Cardiac amyloidosis: updates in diagnosis and management.心脏淀粉样变性:诊断与治疗进展。
Arch Cardiovasc Dis. 2013 Oct;106(10):528-40. doi: 10.1016/j.acvd.2013.06.051. Epub 2013 Sep 23.
5
Cardiac Amyloidosis Detected on Imaging of Patients with Heart Failure.心力衰竭患者影像学检查发现的心脏淀粉样变性。
Am J Case Rep. 2020 Nov 11;21:e926290. doi: 10.12659/AJCR.926290.
6
Progress and challenges in the treatment of cardiac amyloidosis: a review of the literature.心脏淀粉样变治疗的进展与挑战:文献综述。
ESC Heart Fail. 2021 Aug;8(4):2380-2396. doi: 10.1002/ehf2.13443. Epub 2021 Jun 5.
7
Amyloid transthyretin cardiac amyloidosis: diagnosis and management.淀粉样变甲状腺素运载蛋白型心脏淀粉样变性:诊断与管理
Expert Rev Cardiovasc Ther. 2019 Sep;17(9):673-681. doi: 10.1080/14779072.2019.1662723. Epub 2019 Sep 3.
8
Epidemiology and clinical manifestations of cardiac amyloidosis.心脏淀粉样变的流行病学和临床表现。
Heart Fail Rev. 2022 Sep;27(5):1471-1484. doi: 10.1007/s10741-021-10162-1. Epub 2021 Oct 25.
9
Suspicion, screening, and diagnosis of wild-type transthyretin amyloid cardiomyopathy: a systematic literature review.野生型转甲状腺素蛋白淀粉样心肌病的疑诊、筛查和诊断:系统文献回顾。
ESC Heart Fail. 2022 Jun;9(3):1524-1541. doi: 10.1002/ehf2.13884. Epub 2022 Mar 27.
10
The role of echocardiography and 99mTc-HDP scintigraphy in non-invasive diagnosis of cardiac amyloidosis: A case series and literature review.超声心动图和99mTc-HDP骨闪烁显像在心脏淀粉样变性无创诊断中的作用:病例系列及文献综述
Medicine (Baltimore). 2019 Sep;98(38):e17256. doi: 10.1097/MD.0000000000017256.

引用本文的文献

1
Case Series: Genetic mimics of hypertrophic cardiomyopathy in elderly.病例系列:老年人肥厚型心肌病的遗传模拟物
Front Cardiovasc Med. 2025 Jun 12;12:1483390. doi: 10.3389/fcvm.2025.1483390. eCollection 2025.
2
A Tale of Two Diseases: Decoding Aortic Stenosis and Cardiac Amyloidosis.两种疾病的故事:解读主动脉瓣狭窄与心脏淀粉样变
J Clin Med. 2025 Apr 12;14(8):2652. doi: 10.3390/jcm14082652.
3
Changing Treatment Landscape in Transthyretin Cardiac Amyloidosis.转甲状腺素蛋白心脏淀粉样变的治疗格局变化

本文引用的文献

1
AL Amyloidosis for Cardiologists: Awareness, Diagnosis, and Future Prospects: State-of-the-Art Review.心脏病专家的AL淀粉样变性:认识、诊断及未来展望:最新综述
JACC CardioOncol. 2022 Nov 15;4(4):427-441. doi: 10.1016/j.jaccao.2022.08.009. eCollection 2022 Nov.
2
Impact of Earlier Diagnosis in Cardiac ATTR Amyloidosis Over the Course of 20 Years.心脏ATTR 淀粉样变 20 年的早期诊断影响。
Circulation. 2022 Nov 29;146(22):1657-1670. doi: 10.1161/CIRCULATIONAHA.122.060852. Epub 2022 Nov 3.
3
Machine learning algorithms to automate differentiating cardiac amyloidosis from hypertrophic cardiomyopathy.
Circ Heart Fail. 2025 Mar 31:e012112. doi: 10.1161/CIRCHEARTFAILURE.124.012112.
4
Echocardiography reporting in heart failure with preserved ejection fraction: Delphi consensus study.射血分数保留的心力衰竭的超声心动图报告:德尔菲共识研究
Open Heart. 2025 Mar 28;12(1):e003063. doi: 10.1136/openhrt-2024-003063.
5
Echocardiography and Heart Failure: An Echocardiographic Decision Aid for the Diagnosis and Management of Cardiomyopathies.超声心动图与心力衰竭:心肌病诊断与管理的超声心动图决策辅助工具
Curr Cardiol Rep. 2025 Feb 28;27(1):64. doi: 10.1007/s11886-025-02194-y.
6
Advances and challenges in echocardiographic diagnosis and management of cardiac amyloidosis.心脏淀粉样变性的超声心动图诊断与管理的进展及挑战
Int J Cardiovasc Imaging. 2025 Feb 26. doi: 10.1007/s10554-025-03362-5.
7
Clinical and genetic profiles of patients with hereditary and wild-type transthyretin amyloidosis: the Transthyretin Cardiac Amyloidosis Registry in the state of São Paulo, Brazil (REACT-SP).巴西圣保罗州转甲状腺素蛋白心脏淀粉样变登记研究(REACT-SP):遗传性和野生型转甲状腺素蛋白淀粉样变性患者的临床和遗传特征。
Orphanet J Rare Dis. 2024 Jul 20;19(1):273. doi: 10.1186/s13023-024-03281-z.
8
Current Therapies and Future Horizons in Cardiac Amyloidosis Treatment.当前心脏淀粉样变性治疗的疗法和未来展望。
Curr Heart Fail Rep. 2024 Aug;21(4):305-321. doi: 10.1007/s11897-024-00669-7. Epub 2024 May 29.
9
Challenges and Uncertainties in the Diagnosis of Cardiac Amyloidosis: A Case Report.心脏淀粉样变性诊断中的挑战与不确定性:病例报告
Cureus. 2024 May 23;16(5):e60954. doi: 10.7759/cureus.60954. eCollection 2024 May.
10
Extending the reach of expert amyloidosis care: A feasibility study exploring the staged implementation of a UK amyloidosis network.扩展淀粉样变性疾病专家护理的范围:探索英国淀粉样变性网络分阶段实施的可行性研究。
Clin Med (Lond). 2024 Jan;24(1):100004. doi: 10.1016/j.clinme.2023.100004. Epub 2024 Jan 19.
机器学习算法可自动区分心脏淀粉样变性和肥厚型心肌病。
Int J Cardiovasc Imaging. 2023 Feb;39(2):339-348. doi: 10.1007/s10554-022-02738-1. Epub 2022 Oct 19.
4
Transthyretin cardiac amyloidosis.转甲状腺素蛋白心脏淀粉样变性。
Cardiovasc Res. 2023 Feb 3;118(18):3517-3535. doi: 10.1093/cvr/cvac119.
5
Progression of echocardiographic parameters and prognosis in transthyretin cardiac amyloidosis.转甲状腺素蛋白心脏淀粉样变的超声心动图参数进展与预后。
Eur J Heart Fail. 2022 Sep;24(9):1700-1712. doi: 10.1002/ejhf.2606. Epub 2022 Jul 27.
6
Redefining the epidemiology of cardiac amyloidosis. A systematic review and meta-analysis of screening studies.重新定义心脏淀粉样变的流行病学。筛查研究的系统评价和荟萃分析。
Eur J Heart Fail. 2022 Dec;24(12):2342-2351. doi: 10.1002/ejhf.2532. Epub 2022 May 16.
7
Clinical and Genetic Evaluation of People with or at Risk of Hereditary ATTR Amyloidosis: An Expert Opinion and Consensus on Best Practice in Ireland and the UK.爱尔兰和英国遗传性ATTR 淀粉样变患者或有风险者的临床和遗传评估:专家意见和最佳实践共识。
Adv Ther. 2022 Jun;39(6):2292-2301. doi: 10.1007/s12325-022-02139-9. Epub 2022 Apr 13.
8
Clinical Clues and Diagnostic Workup of Cardiac Amyloidosis.心脏淀粉样变性的临床线索与诊断方法。
Methodist Debakey Cardiovasc J. 2022 Mar 14;18(2):36-46. doi: 10.14797/mdcvj.1061. eCollection 2022.
9
Multimodality Imaging in the Evaluation and Prognostication of Cardiac Amyloidosis.心脏淀粉样变性评估与预后的多模态成像
Front Cardiovasc Med. 2022 Mar 24;9:787618. doi: 10.3389/fcvm.2022.787618. eCollection 2022.
10
Long-Term Survival With Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy.用塔法米迪治疗转甲状腺素蛋白淀粉样心肌病患者的长期生存。
Circ Heart Fail. 2022 Jan;15(1):e008193. doi: 10.1161/CIRCHEARTFAILURE.120.008193. Epub 2021 Dec 20.